Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis

[1]  Qin-Hui Tuo,et al.  CHANGES IN microRNA (miR) PROFILE AND EFFECTS OF miR‐320 IN INSULIN‐RESISTANT 3T3‐L1 ADIPOCYTES , 2009, Clinical and experimental pharmacology & physiology.

[2]  D. Rotin,et al.  Deletion of the ubiquitin ligase Nedd4L in lung epithelia causes cystic fibrosis-like disease , 2011, Proceedings of the National Academy of Sciences.

[3]  Zhongming Zhao,et al.  Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma , 2012, PLoS Comput. Biol..

[4]  P. J. Byard,et al.  Effect of high-dose ibuprofen in patients with cystic fibrosis. , 1995, The New England journal of medicine.

[5]  S. Amladi,et al.  Online Mendelian Inheritance in Man 'OMIM'. , 2003, Indian journal of dermatology, venereology and leprology.

[6]  V. McKusick.  Mendelian Inheritance in Man and Its Online Version, OMIM , 2007, The American Journal of Human Genetics.

[7]  Kai Simons,et al.  Lipid rafts and signal transduction , 2000, Nature Reviews Molecular Cell Biology.

[8]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[9]  S. Shen-Orr,et al.  Networks Network Motifs : Simple Building Blocks of Complex , 2002 .

[10]  M. Gregory,et al.  c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells , 2000, Molecular and Cellular Biology.

[11]  Heidi Ledford.  Drug bests cystic-fibrosis mutation , 2012, Nature.

[12]  A. Hatzigeorgiou,et al.  A combined computational-experimental approach predicts human microRNA targets. , 2004, Genes & development.

[13]  M. Weller,et al.  Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis , 2008, Nature Medicine.

[14]  T. W. Geldern.  Faculty Opinions recommendation of Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. , 2010 .

[15]  G. Pier.  Dropping acid to help cystic fibrosis , 2008, Nature Medicine.

[16]  G. Lenoir,et al.  Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? , 1997, The Lancet.

[17]  Austin E. Gillen,et al.  MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. , 2011, The Biochemical journal.

[18]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[19]  R. Dinwiddie,et al.  Reduced upper airway nitric oxide in cystic fibrosis. , 1996, Archives of disease in childhood.

[20]  A. Rosen,et al.  Type I interferons: crucial participants in disease amplification in autoimmunity , 2010, Nature Reviews Rheumatology.

[21]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Noam Shomron,et al.  Pharmaco-miR: linking microRNAs and drug effects , 2013, Briefings Bioinform..

[23]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[24]  N. Rajewsky,et al.  The evolution of gene regulation by transcription factors and microRNAs , 2007, Nature Reviews Genetics.

[25]  S. Storey,et al.  Novel agents in cystic fibrosis , 2008, Nature Reviews Drug Discovery.

[26]  Anton J. Enright,et al.  MicroRNA targets in Drosophila , 2003, Genome Biology.

[27]  E. Mun,et al.  Levamisole inhibits intestinal Cl- secretion via basolateral K+ channel blockade. , 1998, Gastroenterology.

[28]  R. Platt,et al.  Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.

[29]  D. Ray,et al.  Glucocorticoids reduce inflammation in cystic fibrosis bronchial epithelial cells. , 2012, Cellular signalling.

[30]  S. Cialfi,et al.  Synergistic Post-Transcriptional Regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 Specific Binding , 2011, PloS one.

[31]  N. Campbell.  Genetic association database , 2004, Nature Reviews Genetics.

[32]  H. Chan,et al.  MicroRNAs and cystic fibrosis – an epigenetic perspective , 2011, Cell biology international.

[33]  S. Innis,et al.  Plasma choline depletion is associated with decreased peripheral blood leukocyte acetylcholine in children with cystic fibrosis. , 2011, The American journal of clinical nutrition.

[34]  John Goutsias,et al.  Integrative Identification of Deregulated MiRNA/TF-Mediated Gene Regulatory Loops and Networks in Prostate Cancer , 2014, PloS one.

[35]  D. Valle,et al.  Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.

[36]  Bertram Pitt,et al.  Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.

[37]  Mingzhi Liao,et al.  Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses , 2012, Scientific Reports.

[38]  Sean Ekins,et al.  In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.

[39]  Mudita Singhal,et al.  Network Inference Algorithms Elucidate Nrf2 Regulation of Mouse Lung Oxidative Stress , 2008, PLoS Comput. Biol..

[40]  Deborah A. Corey,et al.  Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[41]  Michael Kertesz,et al.  The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.

[42]  M. Corey,et al.  High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. , 2007, The Journal of pediatrics.

[43]  R. Stallings,et al.  miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression , 2010, The Journal of Immunology.

[44]  Pilar Blancafort,et al.  Designing Transcription Factor Architectures for Drug Discovery , 2004, Molecular Pharmacology.

[45]  正博 頭金.  FDA adverse event reporting system (FAERS) , 2015 .

[46]  J. Henney.  Withdrawal of Troglitazone and Cisapride , 2000 .

[47]  H. Einsele,et al.  The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma , 2013, British journal of haematology.

[48]  Yvonne Tay,et al.  A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes , 2006, Cell.

[49]  Vladimir B. Bajic,et al.  Exploration of miRNA families for hypotheses generation , 2013, Scientific Reports.

[50]  M. Hecker,et al.  Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis , 2012, Molecular Neurobiology.

[51]  Ségolène Aymé,et al.  Networking for rare diseases: a necessity for Europe , 2007, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[52]  J. Henney.  Infant Pneumococcal Vaccine , 2000 .

[53]  S. Shen-Orr,et al.  Network motifs: simple building blocks of complex networks. , 2002, Science.

[54]  D. McKay,et al.  TGFbeta down-regulation of the CFTR: a means to limit epithelial chloride secretion. , 2004, Experimental cell research.

[55]  R. Giegerich,et al.  Fast and effective prediction of microRNA/target duplexes. , 2004, RNA.

[56]  An-Yuan Guo,et al.  A Novel microRNA and transcription factor mediated regulatory network in schizophrenia , 2010, BMC Systems Biology.

[57]  Chunxiang Zhang,et al.  MicroRNA-21 in Cardiovascular Disease , 2010, Journal of cardiovascular translational research.

[58]  P. Lebecque,et al.  Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. , 2007, Journal of the American Society of Nephrology : JASN.

[59]  Xiaowei Wang,et al.  Sequence analysis Prediction of both conserved and nonconserved microRNA targets in animals , 2007 .

[60]  L. Tsui,et al.  Phosphatase inhibitors activate normal and defective CFTR chloride channels. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  A. Munnich,et al.  Improvement of cystic fibrosis using antitumoral drugs: a hypothesis. , 2000, Medical hypotheses.

[62]  Robert L. Grossman,et al.  A cis-regulatory map of the Drosophila genome , 2011, Nature.

[63]  O. Hobert.  Gene Regulation by Transcription Factors and MicroRNAs , 2008, Science.

[64]  Weida Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[65]  Xia Li,et al.  SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression , 2013, Bioinform..

[66]  Andrew M. Jones,et al.  Emerging Treatments in Cystic Fibrosis , 2009, Drugs.

[67]  G. Nuovo,et al.  MiR-101 and miR-144 Regulate the Expression of the CFTR Chloride Channel in the Lung , 2012, PloS one.

[68]  Gianluca Damonte,et al.  Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. , 2004, Blood cells, molecules & diseases.

[69]  A. Prince,et al.  Cystic fibrosis: a mucosal immunodeficiency syndrome , 2012, Nature Medicine.

[70]  Rakesh K. Kumar,et al.  Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target , 2011, BMC pulmonary medicine.

[71]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[72]  Juan M. Vaquerizas,et al.  A census of human transcription factors: function, expression and evolution , 2009, Nature Reviews Genetics.

[73]  Gang Feng,et al.  Disease Ontology: a backbone for disease semantic integration , 2011, Nucleic Acids Res..

[74]  Ruchir R. Shah,et al.  Glucocorticoids Modulate MicroRNA Expression and Processing during Lymphocyte Apoptosis* , 2010, The Journal of Biological Chemistry.

[75]  A Garg,et al.  Nuclear transcription factor-κB as a target for cancer drug development , 2002, Leukemia.

[76]  Ashley M. Jacobi,et al.  A microRNA network regulates expression and biosynthesis of wild-type and ΔF508 mutant cystic fibrosis transmembrane conductance regulator , 2012, Proceedings of the National Academy of Sciences.

[77]  M. Konstan,et al.  Inflammation and anti-inflammatory therapies for cystic fibrosis. , 2007, Clinics in chest medicine.

[78]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[79]  Raymond K. Auerbach,et al.  Integrative Analysis of the Caenorhabditis elegans Genome by the modENCODE Project , 2010, Science.

[80]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[81]  Hui Zhou,et al.  ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data , 2012, Nucleic Acids Res..

[82]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[83]  L. Lim,et al.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.

[84]  Deborah A. Corey,et al.  Reduced Smad3 protein expression and altered transforming growth factor-beta1-mediated signaling in cystic fibrosis epithelial cells. , 2001, American journal of respiratory cell and molecular biology.

[85]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[86]  T. Pfeifer.  Diabetes in Cystic Fibrosis , 1992, Clinical pediatrics.

[87]  G. Chrousos,et al.  Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300 , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[88]  C. Gélinas,et al.  To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis , 2003, Oncogene.

[89]  Micah B. Hartman,et al.  National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998. , 2009, Health affairs.

[90]  Cheng Zhu,et al.  Drug repositioning for orphan diseases , 2011, Briefings Bioinform..

[91]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[92]  B. Aggarwal,et al.  Nuclear transcription factor-kappaB as a target for cancer drug development. , 2002, Leukemia.

[93]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[94]  B. Aggarwal,et al.  Nuclear factor-kappa B and cancer: its role in prevention and therapy. , 2002, Biochemical pharmacology.

[95]  Raymond K. Auerbach,et al.  A User's Guide to the Encyclopedia of DNA Elements (ENCODE) , 2011, PLoS biology.

[96]  J. Riordan,et al.  cAMP- and Ca2+-independent Activation of Cystic Fibrosis Transmembrane Conductance Regulator Channels by Phenylimidazothiazole Drugs* , 1996, The Journal of Biological Chemistry.

[97]  H. Pollard,et al.  Elevated miR-155 Promotes Inflammation in Cystic Fibrosis by Driving Hyperexpression of Interleukin-8* , 2011, The Journal of Biological Chemistry.

[98]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[99]  P. J. Barnes,et al.  Increased nitric oxide in exhaled air of asthmatic patients , 1994, The Lancet.

[100]  F. Slack,et al.  Small non-coding RNAs in animal development , 2008, Nature Reviews Molecular Cell Biology.

[101]  K. Flanders,et al.  Smad3 as a mediator of the fibrotic response , 2004, International journal of experimental pathology.